Zenzedi vs Adderall: Understanding the Dangers of Prescription Stimulant Misuse | ISSUP``` ```

```

Zenzedi vs Adderall: Understanding the Dangers of Prescription Stimulant Misuse

A clinical perspective on dextroamphetamine formulations and the serious health consequences of misuse

By Benjamin Zohar, NCACIP | February 7, 2026

Key Takeaway: Zenzedi (dextroamphetamine sulfate) is a Schedule II controlled substance with legitimate medical uses for ADHD and narcolepsy. However, its misuse—particularly through non-oral routes—poses severe and potentially fatal health consequences. If you or...

The ADHD medication shortage entering its third year is pushing patients toward unregulated markets where counterfeit pills laced with fentanyl have become ubiquitous. DEA testing shows 7 out of 10 seized pills contain lethal doses.

Despite DEA efforts to raise production quotas for stimulant medications, the 2025 ADHD shortage continues—driven by deeper manufacturing and distribution issues. Ongoing oversight from agencies like the FDA, DEA, and ASHP is critical, but families and providers still face real-time access challenges. Clearer supply chain policies and responsive pharmacy data could help prevent future disruptions.

Stimulant medications, including Adderall, remain in active shortage across multiple regions in 2025, affecting treatment stability and increasing counterfeit-pill risks. This article explains the latest data behind the shortage and outlines safe, practical steps patients and professionals can take when prescriptions are unavailable.

The 2025 Global Adderall Shortage: Clinical Impact, Public Health Risks, and Implications for Substance Use Professionals

Author: Benjamin Zohar, NCACIP – Nationally Certified Advanced Addiction Intervention Professional, Founder of InterventionNY

This article is intended for education and professional development and does not replace individualized medical, psychiatric, or pharmaceutical consultation.

Summary

The 2025 global shortage of Adderall and related stimulant medications is affecting patient stability, treatment continuity, and public health systems across multiple regions. Driven...